SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is facing intense sell-side pressure as investors express skepticism over the company's aggressive debt-fueled expansion into AI infrastructure and the long-term conversion of its substantial cloud backlog into cash flow. While some traders view the recent descent to 52-week lows as a prime accumulation opportunity for a structural AI play, others are aggressively shorting the stock, citing management silence, credit downgrades, and concerns that demand for AI services may not materialize as projected.

Direxion Shares ETF Trust - Direxion Daily MSCI South Korea Bull 3X ETF

Direxion Daily South Korea Bull 3X Shares

KORU is facing extreme volatility as retail investors grapple with massive margin calls and a significant drawdown from its recent highs, with community discussion intensely focused on the upcoming 20-for-1 stock split and the impact of the SK Hynix IPO. Traders are deeply divided, with many debating whether the current price action represents a classic 'falling knife' or a strategic buying opportunity driven by the underlying strength of the South Korean semiconductor and memory sectors.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded by Keyvan Mohajer, Majid Seyed Emami and James M. Hom on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is facing intense scrutiny as investors debate whether the current price represents a value-driven accumulation phase or a trap, fueled by high short interest and anticipation surrounding the pending LivePerson merger. The community remains deeply divided, with bulls pointing to the company's enterprise footprint and potential short-squeeze catalysts, while bears focus on persistent dilution, cash burn, and the stock's underperformance relative to broader AI sector hype.

Chipotle Mexican Grill, Inc. engages in the business of developing and operating restaurants that serve a relevant menu of burritos, burrito bowls, quesadillas, tacos, and salads made using fresh, high-quality ingredients. The company was founded by Steve Ells in 1993 and is headquartered in Newport Beach, CA.

Chipotle Mexican Grill

Chipotle is facing intense scrutiny as a viral social media trend criticizing portion sizes and higher menu prices sparks a shareholder lawsuit, weighing heavily on investor sentiment. Despite this, community debate remains split between those calling the stock a value-play at multi-year lows and critics who argue that inconsistent quality and aggressive pricing have fundamentally damaged the brand's appeal.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is facing heightened volatility as markets react to escalating geopolitical tensions in the Strait of Hormuz and concerns over a potential rate hike following hawkish commentary from Fed officials. Investors are heavily focused on upcoming CPI data, with community sentiment divided between capitalizing on short-term price swings and bracing for a broader market pullback.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is facing intense volatility as traders debate the sustainability of its AI-driven valuation, with the stock pulling back significantly from its recent highs. The community is sharply divided between those viewing the decline as a long-term accumulation opportunity for AI infrastructure and those expecting further downside as they exit positions once touted as trillion-dollar growth plays.

Factorial Energy, Inc. engages in the development and commercialization of solid-state battery technologies. Its platforms include FEST and Solstice, designed to deliver high-performance, scalable battery solutions for applications in drones, robotics, automotive, and other advanced mobility sectors. The company is headquartered in Billerica, MA.

Factorial Energy Inc. - Ordinary Shares- Class A

Factorial Energy Inc

Factorial Energy is experiencing significant volatility driven by a strategic partnership with Tulip Tech to advance solid-state battery technology for drones. While some community members view the news as a major validation of their commercial potential, others remain skeptical, leading to intense debate over the stock's long-term viability and recent price swings.

Q32 Bio, Inc. operates as a clinical stage biotechnology company developing biologic therapeutics targeting potent regulators of the innate and adaptive immune systems to re-balance immunity in autoimmune and inflammatory diseases. It focuses on the IL-7 / TSLP receptor pathways and complement system, addressing immune dysregulation to help patients take back control of their lives. The company was founded by David Grayzel and Shelia Violette in 2017 and is headquartered in Waltham, MA.

Q32 Bio Inc.

Q32 Bio is experiencing significant volatility and trading momentum following the release of positive 36-week clinical trial data for bempikibart in treating alopecia areata. While retail traders are actively debating the potential for a short squeeze and long-term upside, caution remains high as investors monitor the impact of a recent large-scale public offering and potential dilution on the stock's future performance.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

United States Oil Fund is trending as investors react to renewed airstrikes in Iran and ongoing tensions in the Strait of Hormuz, sparking intense community debate over potential supply disruptions and energy market volatility. Market participants are actively discussing the impact of geopolitical risk premiums, with many questioning whether current price action accurately reflects the severity of the conflict or if it is being driven by algorithmic manipulation.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Sandisk Corp (SNDK) is experiencing intense volatility as investors debate the sustainability of the AI memory demand cycle amid broader semiconductor sector rotation. The stock is a primary focus for traders as community members weigh massive analyst price target revisions against concerns over cyclical peaks and the impact of broader market headwinds like geopolitical tensions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO in Liver-Dominant Metastatic Breast Cancer

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that the first patient has been dosed at the European Institute of Oncology (IEO) in Milan, Italy in its global Phase 2 clinical trial...

Mettler-Toledo (MTD) Soars 3.3%: Is Further Upside Left in the Stock?

Mettler-Toledo (MTD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of two investigator-initiated trials-in-progress abstracts on May 21, 2026. These abstracts will be presented at the 2026...

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Delcath Systems, Inc. (Nasdaq: DCTH) (the Company or Delcath), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Companys Compensation Committee, as material...

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026 at Nasdaq in New...

Delcath Systems, Inc. (DCTH) Reports Q1 Loss, Misses Revenue Estimates

Delcath Systems (DCTH) delivered earnings and revenue surprises of -200.00% and -0.42%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that new data from a retrospective...

Delcath Systems (DCTH) to Release Quarterly Earnings on Thursday

Delcath Systems (NASDAQ:DCTH) will be releasing its Q1 2026 earnings before the market opens on Thursday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-7-delcath-systems-inc-stock...

Delcath Systems to Host First Quarter 2026 Earnings Call

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 7, 2026, at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2026...

Delcath Systems, Inc. (NASDAQ:DCTH) Given Consensus Rating of "Moderate Buy" by Brokerages

Delcath Systems, Inc. (NASDAQ:DCTH - Get Free Report) has been given an average rating of "Moderate Buy" by the six brokerages that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the com...

Delcath Systems, Inc. is an oncology company, which engages in the treatment of primary and metastatic liver cancers. Its products include CHEMOSAT and HEPZATO. The company was founded on August 5, 1988 and is headquartered in Queensbury, NY.

Delcath Systems Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$12.87
Prev Close	$13.01
Open	$13.00
Dividend Yield	0.00%
50-Day Moving Average	$11.60
Beta	1.26
Avg. Volume	614,640.94
PE Ratio	2,168.33

52-Week High	$13.74
52-Week Low	$8.12
Market Capitalization	$449.13M
EPS (Annual)	$0.0676
Price to Book	3.98
Revenue Per Employee	$546,352.56

Feed

News

Sentiment

Earnings

Fundamentals

Info

DCTHDelcath Systems Inc

Latest DCTH News